Randomized, Double-Blinded, Multicenter, Placebo-Controlled Trial of Shenfu Injection for Treatment of Patients with Chronic Heart Failure during the Acute Phase of Symptom Aggravation (Yang and Qi Deficiency Syndrome).
Xianliang WangZhiqiang ZhaoJing-Yuan MaoTinghai DuYuanping ChenHao XuNan LiuXiaolong WangJianguang WuRong LiYong XuYingqiang ZhaoLei WangJingsong HeJun-Hua ZhangJingbo ZhaiGuoyuan ZhaoYazhu HouShuai WangChun-Xiang LiuPublished in: Evidence-based complementary and alternative medicine : eCAM (2019)
SFI combined with conventional therapy for treatment of CHF during acute symptom aggravation ameliorated the cardiac dysfunction and clinical symptoms and improved the patients' quality of life without any significant AEs compared with the conventional therapy alone.
Keyphrases
- double blind
- ejection fraction
- end stage renal disease
- newly diagnosed
- oxidative stress
- prognostic factors
- open label
- randomized controlled trial
- left ventricular
- liver failure
- clinical trial
- replacement therapy
- combination therapy
- hepatitis b virus
- study protocol
- case report
- stem cells
- intensive care unit
- physical activity
- atrial fibrillation
- bone marrow
- drug induced
- phase ii
- patient reported outcomes